Evidence map›Paper›PMID 41613913›Full record

ArticleCase reports in endocrinology2026

Autosplenectomy in a Patient With Autoimmune Polyglandular Syndrome Type 2 (APS-2).

Luqman S Fauzi, Airin Jyoty, Yashwin Sredharan, Manohara Kenchaiah

Abstract read
In one paragraph

Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luqman S FauziDepartment of Diabetes and Endocrinology, Northampton General Hospital, Northampton, UK, nhs.uk.ORCID https://orcid.org/0000-0001-6609-5637
Airin JyotyDepartment of Diabetes and Endocrinology, Northampton General Hospital, Northampton, UK, nhs.uk.
Yashwin SredharanDepartment of Diabetes and Endocrinology, Northampton General Hospital, Northampton, UK, nhs.uk.
Manohara KenchaiahDepartment of Diabetes and Endocrinology, Northampton General Hospital, Northampton, UK, nhs.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune glandular syndrome type 2 is a complex genetic condition where a triad of endocrinopathies is involved, namely, Addison's disease, type 1 diabetes, and/or autoimmune thyroid disorder. The disease predisposes one to a variety of other autoimmune associations. Here, we report a rare presentation of a patient with autoimmune polyglandular syndrome type 2 (APS-2) presenting with a 7-year history of progressive splenic atrophy causing functional hyposplenism that ultimately progressed to anatomical asplenia (autosplenectomy) as demonstrated in the serial imaging. We postulate that the underlying cause of this presentation is also of autoimmune nature. Unlike APS-1, which has been linked to hyposplenism, this is the first reported case of APS-2 with similar splenic involvement. Splenic hypofunction can increase susceptibility to encapsulated bacterial infection, with overwhelming postsplenectomy infection (OPSI) being a significant threat. It is crucial that clinicians recognize the importance of providing guidance on vaccinations, antibiotic chemoprophylaxis, and patient education for individuals with asplenia or hyposplenism. If patients with APS can experience progressive splenic atrophy, we suggest long-term follow-up with splenic function assessment. It is yet unclear whether preemptive screening with pitted red cell count has any clinical impact in this group of patients.

Indexed as

autoimmune polyglandular syndrome type 2 (APS-2)autosplenectomyhyposplenism/aspleniaoverwhelming post-splenectomy infection (OPSI)progressive splenic atrophy

Identifiers

PMID41613913
PMCPMC12849194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.